Merck & Co., Inc. Stock Forecast, Price & News

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 7 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

How has Merck & Co., Inc.'s stock price been impacted by COVID-19?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRK shares have increased by 1.9% and is now trading at $80.75.
View which stocks have been most impacted by COVID-19.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Merck & Co., Inc..

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, February 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Wednesday, October, 27th. The company reported $1.75 EPS for the quarter, topping analysts' consensus estimates of $1.55 by $0.20. The company earned $13.15 billion during the quarter, compared to the consensus estimate of $12.32 billion. Merck & Co., Inc. had a net margin of 14.64% and a trailing twelve-month return on equity of 48.21%. The company's revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.74 EPS.
View Merck & Co., Inc.'s earnings history.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, November 30th. Stockholders of record on Wednesday, December 15th will be paid a dividend of $0.69 per share on Friday, January 7th. This represents a $2.76 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date is Tuesday, December 14th. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.65.
View Merck & Co., Inc.'s dividend history.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.40%. Merck & Co., Inc. has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 97.53%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 40.12% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of $5.650-$5.700 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.770. The company issued revenue guidance of $47.40 billion-$47.90 billion, compared to the consensus revenue estimate of $48.16 billion.

What price target have analysts set for MRK?

16 Wall Street analysts have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $70.00 to $110.00. On average, they expect Merck & Co., Inc.'s stock price to reach $92.07 in the next year. This suggests a possible upside of 14.0% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

• Robert M. Davis, President, Chief Executive Officer & Director
• Caroline A. Litchfield, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
• Sandy Tremps, Vice President-R&D IT CIO
• Dave Williams, Chief Information & Digital Officer
• Franklin K. Clyburn, Executive VP & President-Human Health

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Zogenix (ZGNX).
View all of MRK's competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nordea Investment Management AB (0.48%), Sarasin & Partners LLP (0.16%), Lazard Freres Gestion S.A.S. (0.07%), Retirement Systems of Alabama (0.07%), Royal London Asset Management Ltd. (0.03%) and Value Partners Investments Inc. (0.03%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Coho Partners Ltd., M&G Investment Management Ltd., Nordea Investment Management AB, Retirement Systems of Alabama, Moody National Bank Trust Division, Gradient Investments LLC, Kestra Advisory Services LLC, and State of Alaska Department of Revenue. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Caroline Litchfield, Frank Clyburn, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Foundation Resource Management Inc., Aries Wealth Management, Exchange Traded Concepts LLC, Stonnington Group LLC, AE Wealth Management LLC, XR Securities LLC, and Dixon Hubard Feinour & Brown Inc. VA.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $80.75.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $203.97 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $2.83 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 74,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000, via email at [email protected], or via fax at 908-735-1253.